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BACKGROUND: A randomised trial to ascertain whether women who do not attend for cervical screening are more likely to respond to
the opportunity to collect a self-sample for human papillomavirus (HPV) testing, or to a further invitation to attend for cervical
screening.
METHODS: The study was carried out in a Primary Care Trust (PCT) in London between June 2009 and December 2009. In total, 3000
women were randomly selected from persistent non-responders (i.e., who had not responded to at least two invitations to attend for
screening). The women were randomised on a 1:1 basis to either receive an HPV self-sampling kit or a further invitation to attend
for cervical cytology. The main outcome measures were (1) percentage of women attending for cervical cytology compared with
those returning a self-sample HPV test or attending for cytology subsequent to receiving the kit and (2) percentage of those testing
positive for HPV who attended further investigation.
RESULTS: The total response in the self-sampling group for screening was 10.2%. Of the 1500 women in the control group sent a
further invitation for cervical screening, 4.5% attended for cytology screening. This difference is highly statistically significant
(Po0.0001). Of the 8 women who tested positive for HPV, 7 attended for a cervical smear and had a concurrent colposcopy. Three
of these (43%) had high-grade disease (defined as CIN 2þ), with one found to have an invasive cancer (stage 1b) and one CIN 3.
CONCLUSIONS: The value of this intervention relies on the detection of high-grade CIN and early stage cancer with a good prognosis.
The relatively high yield of abnormalities found is consistent with that expected among a hard to reach and relatively high-risk group
of women. Our study suggests that self-sampling could increase participation among non-responders in England, but further work is
needed to ascertain whether the low response rate seen here is likely to be representative of the rest of the country. Other studies
are needed to investigate the response to self-sampling in different demographic and geographic settings.
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Attendance for cervical screening is falling in England, particularly
among women aged 25–29 years (NHS CSP, 2006; Willoughby
et al, 2006; Lancuck et al, 2008). This is of concern as screening has
been demonstrated to reduce the incidence of cervical cancer yet
coverage of the screening programme has now fallen below its
stated target of 80%. Uptake is considered to be the most
important factor in determining the success of a screening
programme (Weller and Campbell, 2009). Non-attenders are at
higher risk of cervical cancer; therefore, encouraging such women
to take part would save lives and the costs of invasive cancer
treatment. Deprivation and being from an ethnic minority group
are both associated with poor uptake of screening (Webb et al,
2004; Downs et al, 2008; Moser et al, 2009). An NHSCSP survey
(NHS CSP, 2006) and a recent population-based survey (Waller
et al, 2009) have both identified practical issues (such as taking
time off for appointments) as being important in influencing
women’s attendance for screening. These may even be more
important than the emotional issues previously identified as
barriers, such as embarrassment, wish for a female doctor and
discomfort associated with the test (NHS CSP, 2006; Baron et al,
2008; Waller et al, 2009; Wilson, 2009).
One way of increasing coverage and overcoming some of the
practical and emotional barriers to screening attendance might
be to use self-sampling for high-risk human papillomavirus
(HPV) types as a primary screening test for non-attenders.
Human papillomavirus self-sampling has similar sensitivity and
specificity to samples taken by clinicians (Petignat et al, 2007;
Szarewski et al, 2007), and we have shown that it is broadly
acceptable to women (Forrest et al, 2004; Waller et al, 2006;
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sSzarewski et al, 2009). There have been only four published studies
looking specifically at self-sampling in screening non-attenders
carried out in the Netherlands (Bais et al, 2007; Gok et al, 2010),
Sweden (Sanner et al, 2009) and Italy (Giorgi Rossi et al, 2011).
In the Scandinavian studies, 34%, 27% and 39%, respectively, of
non-attenders sent back a self-sample kit which had been posted
to them, compared with 17% in the Dutch study who attended for
screening following a further invitation (in Sweden there was no
control group). However, in the study in Italy, the response was
considerably lower, ranging between 8.7 and 19.6%, depending on
the exact intervention.
If self-sampling does prove acceptable to non-attenders, it would
be possible to make it widely available. There are already
laboratories all around the country which are able to carry out
HPV testing, and it is likely that the numbers and capability will
increase in the near future as HPV testing for the triage of
borderline/mildly abnormal cytology is rolled out from the sentinel
sites. As the samples can be posted to the laboratory, the service
does not have to be available at every hospital, but can be
concentrated in those which have the expertise and capacity.
The cervical screening unit in Westminster Primary Care Trust
(PCT) was set up in 1990. It is responsible for the call, recall and
management of results for the 62000 eligible women in the area.
Westminster PCT is ethnically and culturally diverse, with 27%
of the population classified as non-white (ONS, 2010). Cervical
screening coverage in Westminster in 2008–2009 was 68.1%
overall, 59.7% in the age group 25–49 years and 70.4% in the age
group 50–64 (The Health and Social Care Information Centre,
2009).
The aim of this study was to ascertain whether women who
do not attend for cervical screening are more likely to respond to
the opportunity to collect a self-sample for HPV testing, or to
a further invitation to attend for cervical screening.
In addition, it is important to ascertain whether such women
will attend for further investigation, if they have a positive
screening test (HPV test or cervical cytology). It would be of little
value if the women were persuaded to undergo screening, but then
refused further investigation and treatment.
SUBJECTS AND METHODS
This study was carried out in 2009 using the Exeter National
Health Applications and Infrastructure Services (NHAISs) System
in Westminster PCT. In all, 3000 women were randomly selected
from those identified as persistent non-responders (i.e., had not
responded to at least two invitations to attend for screening,
normally the number sent in the screening programme). These
women were then randomised on a 1:1 basis to either receive an
HPV self-sampling kit or a further invitation to attend for cervical
cytology.
Women randomised to self-sampling were sent a mailing in
June 2009 from the PCT containing an initial contact letter,
a patient information leaflet about the study and consent form in
duplicate (one copy to be returned), an information sheet on how
to perform the test, an HPV information leaflet and the testing kit.
The control group were sent a standard PCT invitation letter for
cervical cytology screening. Both groups received a questionnaire
survey that collected demographic and psycho-social information,
as well as reasons why they had not attended for screening. They
were asked to complete and return it whether or not they took any
further action. Study information was available (both as hard copy
and on the Internet) in Cantonese, Arabic, Farsi, Bengali and
Portuguese, identified as the most prevalent non-English languages
in the area. Women who responded within 6 months of the start
date were included in the analysis.
Women were provided with written and pictorial instructions
detailing how to carry out the self-sampling test. They were also
provided with pre-paid, addressed packaging for the return of the
samples. The self-sampling kit used was the Qiagen sampler
(QIAGEN Ltd, West Sussex, UK), which utilises a cotton swab.
Human papillomavirus testing was carried out using the Qiagen
hybrid capture II (HC-II) test. Results were recorded in relative
light units compared with a 1.0pgml
 1 standard. A positive HPV
result was defined as a value greater or equal to the standard
threshold of 1.0pgml
 1.
Women who had a positive HPV test were invited to attend for
cervical cytology at a dedicated clinic, held in the colposcopy unit
at St Mary’s Hospital, London. When they attended for cervical
cytology, they were offered the option of a colposcopy immediately
following (i.e., at the same visit as) their cytology screen, having
been informed of this choice in advance. The rationale for this was
to save them from having to return for a further gynaecological
examination at a later date should they have an abnormal result. In
addition, those who had a positive HPV test but negative cytology
would have the immediate reassurance of a colposcopy and were
also given the opportunity to discuss the implications in advance.
Women in the control group who had a cervical cytology result
showing mild dyskaryosis or worse were invited for colposcopy at
St Mary’s Hospital, in accordance with routine practice. The
NHAIS Open Exeter database was used to check attendance by all
women contacted (in both groups) for cervical screening and
results as appropriate.
The study was funded by a Research for Patient Benefit (RfPB)
Programme grant: PB-PG-0407-13358 and was approved by the
St Mary’s Research Ethics Committee.
Statistical analysis
A conservative assumption was made, based on the only
comparable published study at the time of preparation (Bais
et al, 2007), of response rates of 15% in the self-sampling group
and 7% in the control group, allowing for 15 and 7% positivity by
HPV and cytology respectively, and allowing for 20% of women on
GP lists to be ‘ghosts’ (i.e., letters sent to an incorrect address).
Thus it was calculated that 1500 women would be needed in each
group to achieve 83% power to detect a significant difference at the
5% significance level between the two groups with regard to the
total proportion responding.
Women in the arm sent a further invitation for screening were
considered to be responders if they attended for cervical screening
between the date of being sent the invitation and up to 6 months
after this date. Women in the self-sampling arm were considered
to be responders if a self-sampling test had been returned within
6 months. We also identified women who had not returned a
self-sampling kit but attended for cervical screening between the
date of being sent the self-sampling kit and up to 6 months after
this date.
We compared the percentage of those attending cervical
screening in the invitation arm and the percentage of those either
returning a self-sample or attending for cervical screening in the
self-sampling arm using a 2 2 tabulation and Pearson’s w
2-test
with one degree of freedom.
Initially, we compared deprivation between responders and non-
responders in the two groups. Deprivation is calculated based on
UK postcodes. Postcodes are categorised into Q1 (most deprived
quintile in the UK) to Q5 (least deprived quintile in the UK) (data
downloaded from GeoConvert: http://geoconvert.mimas.ac.uk/).
Age was compared between the two groups using a Wilcoxon rank
sum test.
Cytology and colposcopy results were taken from the first
cytology resullt recorded after date letter sent (if the intial result
was unsatisfactory, we present the repeat cytology result where
available). Histology is presented as the worst result of the punch
biopsy and LLETZ specimen where taken.
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Figure 1 (flow chart) shows the study design and number of women
who responded. Of 1500 women who were sent a self-sampling kit,
96 (6.4%) returned a self-sample and 105 (7%) returned a
questionnaire (93 returned both a self-sample and questionnaire).
A further 57 women (3.8%) sent a self-sampling kit who did not
return it attended for a routine cervical screen. Therefore, the total
response in the self-sampling group for screening was 10.2%. Of the
1500 women in the control group sent a further invitation for
cervical screening, 68 (4.5%) attended for cytology screening
between June 2009 and December 2009. This difference is highly
statistically significant (Po0.0001). In all, 106 of the women in the
cytology screening group (7%) returned a questionnaire.
The median age overall was 48 years, with a range of
29–65 years (IQR 41–57 years). There was little difference in
age distribution between responders and non-responders in the
two groups (Figure 2): in the self-sampling group, the median
age for responders was 47.5 years (IQR 40.5–54.5 years), while
for the non-responders the median age was 47 years (IQR
40–57 years), P-value¼0.68. In the further invitation for cervical
cytology group the median age for responders was 46.5 years
(IQR 40–52 years), while for the non-responders the median age
was 48 years (IQR 41–57 years), P-value¼0.19. The overall
proportion of women under the age of 35 years was 5.7% and was
similar in all groups. Table 1 compares the social deprivation
scores in the two groups; it can be seen that there is little difference
between them.
For those 96 women who returned a self-sample, 95 (99.0%)
were adequate (one sample tube arrived containing no liquid). In
all, 8 out of 95 (8.3%) had a positive HC-II result. One woman did
not respond to the subsequent invitation to attend for cervical
cytology. She confirmed her attendance at a private clinic for
cervical cytology subsequent to her HPV test, and that the result
was negative. The remaining seven women attended for cervical
cytology and all of them took up the offer of an immediate
colposcopy. Table 2 shows the outcome of cytology and histology.
Where women had both a punch biopsy and a loop excision
(LLETZ), the worst histology is given. Taking the worst histology
result, 3 (43%) had high-grade disease (defined as CIN 2þ), with
one found to have an invasive cancer (stage 1b) and one CIN 3.
3000 non-responders to at least 2
invitations to attend for cervical
screening
Sent HPV self-sampling kit +
questionnaire
n= 1500
Sent cervical cytology
invitation + questionnaire
n = 1500
1 : 1 randomisation
Questionnaire
returned n=105
Questionnaire
returned n=106
Self-sample
returned
n= 96 (6.4%)
Self-sample not
returned
n= 1404 (93.6%)
Attended for
cervical cytology
n= 68 (4.5%)
No response to
invitation
n= 1432 (95.5%)
Attended for
cervical cytology
n= 57  (4.1%)
Figure 1 Overview of study design.
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Figure 2 Age distribution of 3000 women in the study.
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self-sample, 57 attended for cervical cytology within the following
6 months (i.e., 57 out of 1404 or 4.1%). In all, 50 (87.7%) had a
negative cytology result, 2 (3.5%) had borderline/mild dyskaryosis
and in 5 cases (8.8%) the sample was inadequate for diagnosis.
In all, 68 of the 1500 (4.5%) women sent a further invitation for
cytology screening (the control group), attended. Table 3 shows
their results. One woman was found to have severe dyskaryosis;
she had CIN2/3 on punch biopsy and CIN3 on the loop specimen.
Reasons for non-attendance
In total, 211 questionnaires were received (i.e., a 7% response rate).
In total, 105 were from women randomised to receive a self-sample
kit and 106 were from those randomised to receive a further
invitation for cytology screening. In total, 180 of the women gave
at least one reason for previous non-attendance for screening. A
number of themes were apparent (Table 4), which related to the
unpleasant/embarrassing nature of the examination, practical
issues such as lack of time, problems with transport, making
appointments and perceptions of being at low risk for disease.
Thirty women in the self-sampling group and 39 in the control
group had actually attended for cytology screening in the 3 months
before the study, but their results had not yet been entered onto
the system when the study letters were generated.
DISCUSSION
The response rate in Westminster PCT in this study was
considerably lower than in the three studies of non-responders
in the Netherlands and Sweden (Bais et al, 2007; Sanner et al, 2009;
Gok et al, 2010). Those studies showed response rates for HPV
self-sampling of 34, 39 and 27%, respectively, whereas the response
rate in this study to self-sampling was 6.4%, with a further 3.8%
of those sent self-sampling kits attending for cytology screening.
This brings the response rate in the self-sampling group to
10.2% compared with 4.5% in the cytology screening group. Only
7% of women returned the questionnaire in both the study and
control groups. The response rate in the Italian study (Giorgi Rossi
et al, 2011), while lower than in the other studies, was still higher
than in Westminster PCT. However, it should be noted that the
population in the Italian study was somewhat different, in that
the women (aged 35–65 years) were eligible when they had missed
only one invitation, and were o5 months late for screening
attendance.
Table 1 Comparison of social deprivation scores in the two groups (ascertained by postcode)
Self-sampling group Cervical cytology group
Responders Non-responders Total Responders Non-responders Total
Q1 (most deprived) 23 (5.1%) 430 (94.9%) 453 16 (4.0%) 386 (96.0%) 402
Q2 26 (6.6%) 367 (93.4%) 393 17 (4.0%) 403 (96.0%) 420
Q3 23 (6.4%) 336 (93.6%) 359 17 (4.5%) 357 (95.5%) 374
Q4 24 (8.3%) 264 (91.7%) 288 18 (6.1%) 278 (93.9%) 296
Q5 (most affluent) 0 (0.0%) 7 (100.0%) 7 0 (0.0%) 8 (100.0%) 8
Total 96 1404 1500 68 1432 1500
Responders are defined as women returning a self-sample or attending for cytology screening (not whether they returned a questionnaire). Crown Copyright 2006.
Source: National Statistics/Ordnance Survey; extracts are Crown Copyright and may only be reproduced by permission.
Table 2 Histology results in the women who tested HPV positive
Worst histology
Cytology
No
biopsy
taken
HPV
only
CIN
1
CIN
2
CIN
3
Invasive
cancer
stage 1B Total
Negative 2 1 — — — — 3
Borderline
dyskaryosis
—— — 1 — — 1
Moderate
dyskaryosis
—— 1— — — 1
Severe
dyskaryosis
—— — —1 1 2
Total 2 1 1 1 1 1 7
Abbreviations: CIN¼cervical intraepithelial neoplasia; HPV¼human papillomavirus.
Table 3 Cytology results of the 68 women who responded to the
further invitation to attend for cytology screening
Cytology result Number (%)
Inadequate 3 (4.4%)
Negative 62 (91.2%)
Borderline dyskaryosis 2 (2.9%)
Severe dyskaryosis 1 (1.5%)
Total 68
Table 4 Reason for non-attendance of cervical screening: taken from
questionnaire
Reason n
Emotional or attitudinal reasons
Uncomfortable/painful/unpleasant/sexual abuse/dislike
doctors or nurses
62
Embarrassed 48
No recent sexual activity/no problems/too old or young
(incorrect perception of risk)
23
Putting off/not important/forgetting 22
Frightened to be told had cancer 18
Other 6
Practical reasons
Lack of time/too busy/no child care/access to clinic/times/
transport/disabled
49
Never had sex 17
Hysterectomy/operation – unnecessary 9
Attend elsewhere (abroad/privately) 8
Other 3
Unknown
Other 9
Total 274
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current practice within the NHS cervical screening programme and
to have a similar intervention level in both the study and control
arms. In contrast, the non-responders in the studies in Sweden and
the Netherlands were contacted more than once to encourage them
to participate. In addition, despite non-attendance being identified
as a particular problem in the UK in women under 35 years, in this
study under 35s accounted for o10% of the population. This is
because we chose to target women who had not responded to at
least two invitations; if screening starts at 25 years and is rolled out
over 3 years, women will be well over 30 years by the time they fall
into this category. The timing of this study coincided with a high
level of publicity regarding the death from cervical cancer of the
celebrity Jade Goody. This resulted in increased levels of
attendance for cervical screening throughout the country (Bowring
and Walker, 2010). This may have encouraged some non-attenders
to go for the established cytology test, rather than to perform a
self-sample. Indeed, 3.8% of those in the self-sampling group (57
out of 1500) attended for cytology rather than sending back a self-
sample. However, it is unlikely that this was a major factor, as the
uptake of cervical screening in the control arm of the study was
only 4.5%. Westminster PCT has a high level of population
mobility, with an annual population turn over of 390 per 1000
registered GP patients in 2007–2008 (Guy, 2009). As a result, it is
not possible to be certain that invitations actually reached the
women invited. In the studies in Sweden and the Netherlands it is
likely that the population was better defined due to the presence in
both countries of identity numbers. In addition, those studies
excluded women who were not eligible for routine screening, for
example, those who had undergone hysterectomy. In the UK, this
information is dependent on the patient being removed by GPs
from the Patient Notification Lists, and their accuracy is variable.
Unfortunately the 7% response rate to the return of the
questionnaires is too low to be considered representative.
Although the study information was available in other languages
(and this was stated in these languages in the information sent), we
did not receive any requests for translations. In all, 90% of women
who returned a questionnaire stated that they had lived in the UK
for 410 years and that their preferred language was English. The
way information is presented can be very important in influencing
women’s decisions regarding screening (Giordano et al, 2008;
Weller and Campbell, 2009). However, it is interesting to note, in
relation to those women who chose to respond, that the prevalent
themes were similar to those identified in a recent population-
based interview study of 580 women in England (Waller et al,
2009). In that study, the most endorsed barriers to attendance for
screening were embarrassment with regard to the examination,
fear of what the test might find, fear of pain, lack of time or not
getting around to attending, perceived difficulties in arranging a
convenient appointment and having had a bad screening
experience in the past. Self-sampling for HPV could be a way of
removing some of these barriers (e.g., the embarrassment, the fear
of pain and the time required to go to a clinic) and may indeed be a
solution for some, but not all women (Forrest et al, 2004; Szarewski
et al, 2009). Cultural sensitivities need to be taken into account
and, given the low response rate in this study, more studies in the
UK are needed before any decisions are taken regarding
implementation of such a strategy.
The HPV positivity rate in this study, at 8.2%, was similar to that
found in a screening study in a comparable age group in the UK
(Cuzick et al, 2003), in which the HC-II test was used. In England
and Wales, approximately one woman in 10000 screened is found
to have invasive cancer (NHS CSP, 2009).
In this study, 8 out of 96 women screened by self-sampling tested
positive for high-risk HPV. Seven of these women attended for
colposcopy, high-grade disease was detected in three (43%) with one
found to have CIN 3 and one an invasive cancer (stage 1b).
In the study by Giorgi Rossi et al (2011), it was calculated that 13
self-sampling kits had to be sent out for every one that was
returned from women who had not attended for screening within 3
years (the subgroup closest to this study). In Westminster PCT, the
corresponding number is 16. We have estimated that the
administrative, laboratory and colposcopy costs of our study
(i.e., not specifically related to the research aspects) could be as
much as d13k for the self-sampling group, but only if using a
commercial rate for the HPV tests of d42 per test. It is anticipated
that the cost of HPV testing will decrease once it is adopted into
the NHS for triage of borderline cytology and follow-up of women
who have been treated for CIN. Indeed, this is already ongoing in
the sentinel sites (NHS CSP, 2011), and is due to be rolled out
nationwide during 2011. Nevertheless, this study suggests that
savings of at least this amount can be expected by increasing the
uptake of screening among high-risk women. Even on the
conservative assumption of between two and three cancers
prevented among the six additional abnormalities detected,
savings exceeding d15k are anticipated applying the costs of the
care pathway for screen detected cancers set out in the ARTISTIC
study (Kitchener et al, 2009). The value of this intervention relies
on the detection of high-grade CIN and early stage cancer with a
good prognosis. The relatively high yield of abnormalities found is
consistent with that expected among a hard to reach and relatively
high-risk group of women. The albeit limited success of the
approach would certainly seem to merit further investigation.
Our study suggests that self-sampling could increase participa-
tion among non-responders in England, but further work is
needed to ascertain whether the low response rate seen here is
likely to be representative of the rest of the country. Other studies
should now be carried out to investigate the response to self-
sampling and its cost effectiveness in different demographic and
geographic settings.
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